Chronic oral and maxillofacial pain conditions represent a diverse group of disorders. Broadly, they can be broken down into temporomandibular disorders (TMDs) and/or orofacial pain disorders. These classifications further detail a series of conditions ranging from joint pains, muscles pains, headaches, to various neuralgias of the head, neck, and face. The presence of depression often complicates these conditions. In addition, chronic noxious stimuli can lead to central sensitization, amplifying and protracting pain. Ketamine, a commonly used general anesthetic agent, has been studied in pre-clinical animal and human clinical trials and has shown great promise for treating chronic pain and depression. It has also been proposed that intravenous ketamine administration plays a role in reversing central sensitization. Albeit simplified, the hypothesized mechanism of action behind ketamine's ability to perform these actions primarily lies within the drug's ability to inhibit N-methyl-D-aspartate receptors (NMDAR) in the central nervous system. However, it is thought that other factors are at play behind ketamine's clinically valuable attributes. Unfortunately, most research in this field has been studied without regard to the head, neck, and face. The following is a systematized review of ketamine therapy to treat such disorders. Regrettably, the results demonstrated the dental profession's lack of pursuit in ketamine therapy when treating chronic oral and maxillofacial pain patients. Nevertheless, there was a meaningful amount of data covering the utility of ketamine therapy. Although most clinical trials present with large degrees of design heterogenicity, the overwhelming conclusion of these publications suggests great promise for the use of intravenous ketamine infusions to treat a multitude of chronic pain conditions. Given these results, the dental profession, with its recent addition of two new specialties (i.e., dental anesthesiology and orofacial pain), alo (open full item for complete abstract)